Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
Official title:
The STRAVI study investigates the molecular pathways distinguishing repigmented and non-repigmented lesions in vitiligo during standard combination therapy. Using advanced transcriptomic and serum analysis, this research aims to uncover key factors influencing treatment response. Participants will receive oral mini-pulse methylprednisolone (16 mg twice weekly) combined with Narrowband UVB (Nb-UVB) phototherapy (twice weekly) over 24 weeks. Skin and blood samples will be collected to assess pro-inflammatory cytokines, chemokines, and transcriptomic profiles.
Key Details
- Age Range: 18 to 65 years
- Estimated Enrollment: 10 participants
- Treatment Duration: 24 weeks
Procedures
- Skin Biopsies: One 4mm biopsy from the forearm at baseline; two 4mm biopsies at months 3 and 6 from the same lesion (repigmented and non-responded areas). Samples will undergo same-day single-cell RNA sequencing (scRNA-seq).
- Blood Samples: 30 mL collected at weeks 0, 12, and 24 to measure pro-inflammatory cytokines and chemokines.
For a complete list of inclusion and exclusion criteria, interested individuals should contact the study team or visit the official ClinicalTrials.gov page (NCT05927272). Only the research staff can determine if a person fully qualifies for the study.
The VRF will continue to monitor the progress of this trial and provide updates as they become available. We encourage eligible individuals to consider participating in this important research effort to advance vitiligo treatment.
Start date: 2024-04-10
Completion date: 2025-10-09
Contact: Julien SENESCHAL, MD, PhD
Tel.: +33 (0)5 56 79 49 63
Email: julien.seneschal@chu-bordeaux.fr
Link: https://clinicaltrials.gov/study/NCT05927272
FAQOther Questions
- Can chemicals cause vitiligo?
Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
- How Vitiligo Changes with Age?
Vitiligo, a condition characterized by the loss of skin pigmentation, can affect individuals at any stage of life. While it often appears before the age of 20, its progression a...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.